Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.
Scope of the Report:
The global average gross margin of Gastrointestinal is in a slight decreasing trend, and the gross margin is 63% in 2015.
Europe region is the largest supplier of Gastrointestinal, with a production revenue market share nearly 50% in 2015. North America is the second largest supplier of Gastrointestinal, enjoying production revenue market share nearly 22% in 2015.
North America is the largest consumption place, with a consumption value market share nearly 52% in 2015. Following North America, Europe is the second largest consumption place with the consumption value market share of 22% in 2015.
Market competition is intense. AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, etc. are the leader ...
Table of Contents
1 Market Overview
1.1 Gastrointestinal Introduction
1.2 Market Analysis by Type
1.2.1 Prescription Gastrointestinal Drug
1.2.2 OTC Gastrointestinal Drug
1.3 Market Analysis by Applications
1.3.1 Chronic Gastritis
1.3.2 Functional Dyspepsia
1.3.3 Peptic Ulcer
1.3.4 Acute Gastroenteritis
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
126.96.36.199 United States Market States and Outlook (2014-2024)
188.8.131.52 Canada Market States and Outlook (2014-2024)
184.108.40.206 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
220.127.116.11 Germany Market States and Outlook (2014-2024)
18.104.22.168 France Market States and Outlook (2014-2024)
22.214.171.124 UK Market States and Outlook (2014-2024)
126.96.36.199 Russia Market States and Outlook (2014-20 ...